Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Nectar
company
About
Nectar builds a comprehensive, vertically integrated allergy healthcare platform leveraging data and clinical research.
- New York,New York,United States
- 11 - 50
- https://www.mynectar.com
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $16.50M
- Industries
- Clinical Trials,Health Care,Health Diagnostics,Medical,Pharmaceutical,Therapeutics
- Founded date
- Jan 1, 2021
- Number Of Employee
- 11 - 50
- Operating Status
- Active
- Legal Name
- Nectar Life Sciences, Inc.
- Also Known As
- Nectar Life Sciences
Nectar builds a comprehensive, vertically integrated allergy healthcare platform leveraging data and clinical research. The company was founded in 2021 and is headquartered in New York.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$24.50M
Nectar has raised a total of
$24.50M
in funding over 2 rounds. Their latest funding was raised on
Dec 20, 2022 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 20, 2022 | Series A | $16.50M | 3 |
|
— | Detail |
| Mar 16, 2022 | Seed | $8M | 2 |
Juxtapose
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
2
3
Nectar is funded by 3 investors.
Harmony Partners
and Juxtapose
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Series A |
|
Juxtapose
|
— | Series A |
Obvious Ventures
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
